Vertebral plasmacytoma

Mechanism and manifestations

It may cause pain, bone destruction, fracture or neural compression. An apparently single lesion on local imaging does not establish that it is solitary.

Diagnosis and management

Assessment combines sampling, blood and urine tests, marrow evaluation and appropriate imaging. Radiotherapy may treat a solitary form; instability or compression may require a spinal procedure. Hematology follow-up remains essential.

Points to consider

Benign and malignant describe biological behavior, but a benign lesion can still compress neural tissue or weaken bone. Precise diagnosis depends on context, imaging and sometimes tissue analysis. Progressive pain with weakness or sphincter changes requires prompt assessment.

Role of TAGMED care

This condition first requires medical diagnosis and, depending on the situation, specialist management. TAGMED services do not replace treatment of infection or tumor, stabilization of an unstable injury, or neurological or vascular treatment. Any conservative support should be considered only after diagnosis, restrictions and the treating team’s recommendations have been clarified.

Related concepts and distinctions

These concepts belong to the same field, but are not synonyms.

• Spinal cord astrocytoma — Glial tumor arising within the spinal cord from astrocytic-lineage cells, with variable grade.
• Multiple myeloma involving the spine — Plasma-cell cancer that can weaken vertebrae through bone lesions and cause pain, fractures or neurological compression.
• Spinal osteoblastoma — Usually benign bone-forming tumor that can affect the spine and behave locally aggressively.

Medical references

1. National Cancer Institute. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ).
2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Bone health and osteoporosis.

References document the topic; their inclusion does not imply endorsement of TAGMED services by those organizations.